MNPR · Monopar Therapeutics

Monopar Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Developing A Treatment For Wilson Disease And Novel Radiopharmaceuticals For Oncology. Its Wilson Disease Product Candidate Is Alxn1840, A Late-Stage, Investigational Once-Daily, Oral Medicine. The Group Radiopharmaceutical Programs Consist Of Phase 1-Stage Mnpr-101-Zr For Imaging Cancers, And Phase 1a-Stage Mnpr-101-Lu And Late Preclinical-Stage Mnpr-101-Ac For The Treatment Of Cancers That Express Urokinase Plasminogen Activator Receptor (Upar). It Build Drug Development Pipeline Through Both In-House Efforts And Licensing Of Late Preclinical- And Clinical-Stage Therapeutics. The Company Operates As A Single Reportable Segment, Focusing On The Development Of Clinical And Preclinical Product Candidates.